The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
disease (COVID-19) has posed a serious threat to global health. As no specific therapeutics …

The IMPACC cohort, composed of> 1,000 hospitalized COVID-19 participants, contains five
illness trajectory groups (TGs) during acute infection (first 28 days), ranging from milder (TG1 …

SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies |
Nature Medicine Skip to main content Thank you for visiting nature.com. You are using a …

A subset of COVID-19 patients exhibit post-acute sequelae of COVID-19 (PASC), but little is
known about the immune signatures associated with these syndromes. We investigated …

Severe COVID-19 is rare in previously healthy individuals who are less than 50 years of
age, affecting probably no more than 1 in 1,000 such infected individuals. We suggest that …

In the midst of resurging COVID-19 cases, the second NIH/FDA virtual COVID-19 and
Cytokines symposium was held on 1 December 2020, focusing on longitudinal studies of …

More than one year since its emergence, corona virus disease 2019 (COVID-19) is still
looming large with a paucity of treatment options. To add to this burden, a sizeable subset of …

Non-human primate models will expedite therapeutics and vaccines for coronavirus disease
2019 (COVID-19) to clinical trials. Here, we compare acute severe acute respiratory …

Viral shedding patterns and their correlations with immune responses are still poorly
characterized in mild coronavirus (CoV) disease 2019 (COVID-19). We monitored shedding …

COVID-19 pathogenesis is associated with an exaggerated immune response. However, the
specific cellular mediators and inflammatory components driving diverse clinical disease …